Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population

Prostate

Volumn 70, Issue 15, 2010, Pages 1716-1727

  Agalliu, Ilir ^a   Leanza, Suzanne M ^a   Smith, Lorie ^a   Trent, Jeffrey M ^b   Carpten, John D ^c   Bailey Wilson, Joan E ^c   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Founder population; Genetic susceptibility; HPCX; Prostate cancer; RNASEL

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; GENE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HPCX GENE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROSTATE CANCER; RNASEL GENE; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; CASE CONTROL STUDY; CHEMISTRY; CHI SQUARE DISTRIBUTION; GENETIC PREDISPOSITION; GENETICS; JEW; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATE TUMOR;

DNA; MICROSATELLITE DNA; PPPA(2'P5'A)N DEPENDENT RIBONUCLEASE; PPPA(2'P5'A)N-DEPENDENT RIBONUCLEASE; RIBONUCLEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DNA, NEOPLASM; ENDORIBONUCLEASES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; JEWS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 77958499693     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21207     Document Type: Article

References (50)

1. American Cancer Society (ACS). Cancer Facts and Figures: 2009.
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K,. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78 -85.
3. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P,. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer 2003; 107: 797 -803.
4. Zeegers MP, Jellema A, Ostrer H,. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta-analysis. Cancer 2003; 97: 1894 -1903.
5. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ, International Consortium for Prostate Cancer G. Where are the prostate cancer genes? A summary of eight genome wide searches. Prostate 2003; 57: 261 -269.
6. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D,. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005; 77: 219 -229.
7. Schaid DJ,. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13: R103 -R121.
8. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM, Isaacs WB,. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371 -1374.
9. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J,. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20: 175 -179.
10. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J,. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181 -184.
11. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH,. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 1993; 12: 3297 -3304.
12. Zhou A, Hassel BA, Silverman RH,. Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action. Cell 1993; 72: 753 -765.
13. Silverman RH,. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805 -1812.
14. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS,. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581 -583.
15. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y, Orr-Urteger A,. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981 -984.
16. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J,. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70: 1299 -1304.
17. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN,. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 2002; 71: 116 -123.
18. Chen H, Griffin AR, Wu YQ, Tomsho LP, Zuhlke KA, Lange EM, Gruber SB, Cooney KA,. RNASEL mutations in hereditary prostate cancer. J Med Genet 2003; 40: e21.
19. Cunningham JM, McDonnell SK, Marks A, Hebbring S, Anderson SA, Peterson BJ, Slager S, French A, Blute ML, Schaid DJ, Thibodeau SN, Mayo Clinic RM,. Genome linkage screen for prostate cancer susceptibility loci: Results from the mayo clinic familial prostate cancer study. Prostate 2003; 57: 335 -346.
20. Kotar K, Hamel N, Thiffault I, Foulkes WD,. The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 2003; 40: e22.
21. Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK, Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C, Giri V, Dimmer JB, Montie JE, Trent JM, Cooney KA,. Genome-Wide Scan for Prostate Cancer Susceptibility Genes Using Families From the University of Michigan Prostate Cancer Genetics Project Finds Evidence for Linkage on Chromosome 17 Near Brca1. Prostate 2003; 57: 326 -334.
22. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H,. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 2003; 89: 691 -696.
23. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV,. Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocr Relat Cancer 2003; 10: 225 -259.
24. Malathi K, Paranjape JM, Ganapathi R, Silverman RH,. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2-,5-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2004; 64: 9144 -9151.
25. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB,. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6 -11, discussion S11-S12.
26. Nupponen NN, Wallen MJ, Ponciano D, Robbins CM, Tammela TL, Vessella RL, Carpten JD, Visakorpi T,. Mutational analysis of susceptibility genes Rnasel/Hpc1, Elac2/Hpc2, and Msr1 in sporadic prostate cancer. Genes Chromosomes Cancer 2004; 39: 119 -125.
27. Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, Adami HO, Augustsson-Balter K, Gronberg H,. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10: 7150 -7156.
28. Maier C, Haeusler J, Herkommer K, Vesovic Z, Hoegel J, Vogel W, Paiss T,. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 2005; 92: 1159 -1164.
29. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, Leonard DG, Wein A, Malkowicz SB, Rebbeck TR,. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005; 14: 949 -957.
30. Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Ben Baruch G, Friedman E, Gershoni-Baruch R,. The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Fam Cancer 2006; 5: 389 -395.
31. Li H, Tai BC,. RNASEL gene polymorphisms and the risk of prostate cancer: A meta-analysis. Clin Cancer Res 2006; 12: 5713 -5719.
32. Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H,. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15: 474 -479.
33. Cybulski C, Wokolorczyk D, Jakubowska A, Gliniewicz B, Sikorski A, Huzarski T, Debniak T, Narod SA, Lubinski J,. DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 2007; 79: 44 -49.
34. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang WY, Isaacs WB, Platz EA,. RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 2007; 67: 849 -854.
35. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ,. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007; 13: 5959 -5964.
36. Larson BT, Magi-Galluzzi C, Casey G, Plummer SJ, Silverman R, Klein EA,. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 2008; 179: 1344 -1348.
37. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA,. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate 2008; 68: 1790 -1797.
38. Shea PR, Ishwad CS, Bunker CH, Patrick AL, Kuller LH, Ferrell RE,. RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans. Prostate 2008; 68: 354 -359.
39. Summers K, Crespi B,. Molecular evolution of the prostate cancer susceptibility locus RNASEL: Evidence for positive selection. Infect Genet Evol 2008; 8: 297 -301.
40. Lange EM, Chen H, Brierley K, Perrone EE, Bock CH, Gillanders E, Ray ME, Cooney KA,. Linkage analysis of 153 prostate cancer families over a 30-CM region containing the putative susceptibility locus HPCX. Clin Cancer Res 1999; 5: 4013 -4020.
41. Peters MA, Jarvik GP, Janer M, Chakrabarti L, Kolb S, Goode EL, Gibbs M, DuBois CC, Schuster EF, Hood L, Ostrander EA, Stanford JL,. Genetic linkage analysis of prostate cancer families to Xq 27-28. Hum Hered 2001; 51: 107 -113.
42. Bochum S, Paiss T, Vogel W, Herkommer K, Hautmann R, Haeussler J,. Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families. Prostate 2002; 52: 12 -19.
43. Brown WM, Lange EM, Chen H, Zheng SL, Chang B, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cooney KA,. Hereditary prostate cancer in African American families: Linkage analysis using markers that map to five candidate susceptibility loci. Br J Cancer 2004; 90: 510 -514.
44. Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LA,. Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 2005; 116: 179 -185.
45. Agalliu I, Gern R, Leanza S, Burk RD,. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009; 15: 1112 -1120.
46. Baffoe-Bonnie AB, Smith JR, Stephan DA, Schleutker J, Carpten JD, Kainu T, Gillanders EM, Matikainen M, Teslovich TM, Tammela T, Sood R, Balshem AM, Scarborough SD, Xu J, Isaacs WB, Trent JM, Kallioniemi OP, Bailey-Wilson JE,. A major locus for hereditary prostate cancer in Finland: Localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet 2005; 117: 307 -316.
47. Breslow NE, Day NE,. Statistical methods in cancer research, Vol. 1-The analysis of case-control studies. Lyon: International Agency for Research on Cancer; 1980.
48. Klienbaum DG, Nizam A, Kupper L, Muller KE,. Applied regression analysis and multivariate methods, 4th edition. Pacific Grove, CA: Duxbury Press; 2007.
49. Dubin N, Pasternack BS,. Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol 1986; 123: 1101 -1117.
50. Gronberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, Bova GS, Danber JE, Bergh A, Walsh PC, Collins FS, Trent JM, Meyers DA, Isaacs WB,. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997; 57: 4707 -4709.